StroMel (Autologous mesenchymal stem cells)
/ Akan Bio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 29, 2025
Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint
(clinicaltrials.gov)
- P1/2 | N=20 | Not yet recruiting | Sponsor: Akan Biosciences, LLC | Trial completion date: Dec 2022 ➔ Aug 2027 | Trial primary completion date: Dec 2022 ➔ Aug 2027
Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology
February 17, 2022
Safety and Tolerability of StroMel™ in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
(clinicaltrials.gov)
- P1/2 | N=20 | Not yet recruiting | Sponsor: Akan Biosciences, LLC | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Dec 2022
Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology
February 16, 2021
Akan Biosciences Announces FDA Acceptance of IND Application for StroMel in Osteoarthritis of Knee
(PRNewswire)
- "Akan Biosciences...today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) for StroMel™, its lead candidate for the treatment of Osteoarthritis of Knee...The clinical trial is scheduled to initiate in March 2021."
IND • Trial initiation date • Osteoarthritis • Pain
1 to 3
Of
3
Go to page
1